Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Invested Capital (2021 - 2025)

Historic Invested Capital for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $535.4 million.

  • Kiniksa Pharmaceuticals International's Invested Capital rose 2251.16% to $535.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $535.4 million, marking a year-over-year increase of 2251.16%. This contributed to the annual value of $438.4 million for FY2024, which is 9.18% down from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Invested Capital stood at $535.4 million, which was up 2251.16% from $495.0 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Invested Capital peaked at $535.4 million during Q3 2025, and registered a low of $153.5 million during Q2 2022.
  • For the 5-year period, Kiniksa Pharmaceuticals International's Invested Capital averaged around $362.2 million, with its median value being $405.1 million (2023).
  • Its Invested Capital has fluctuated over the past 5 years, first tumbled by 3858.65% in 2022, then skyrocketed by 16819.03% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Invested Capital (Quarter) stood at $185.0 million in 2021, then skyrocketed by 114.09% to $396.1 million in 2022, then increased by 10.78% to $438.8 million in 2023, then decreased by 0.09% to $438.4 million in 2024, then rose by 22.11% to $535.4 million in 2025.
  • Its last three reported values are $535.4 million in Q3 2025, $495.0 million for Q2 2025, and $457.5 million during Q1 2025.